EKF Diagnostics Holdings plc, the AIM-listed global diagnostics business, announces the launch of its new Biosen C-Line , an advanced version of its industry leading rapid benchtop glucose and lactate analyzer. Image Credit: EKF Diagnostics The new and updated analyzer has been designed to enhance usability with the latest colour, touch screen and advanced connectivity, enabling the Biosen C-Line to seamlessly connect with hospital and laboratory IT systems, via EKF Link , to ensure patient results are quickly and securely available to clinicians. The Biosen C-Line analyzer measures glucose and lactate levels in whole blood, plasma and serum, using enzymatic sensor technology to give highly precise results, less than 3% CV.
It is used by clinical professionals in both primary and secondary care settings around the world to provide fast and accurate glucose analysis for the detection and management of diabetes, a chronic condition which is expected to affect 1.31 billion people worldwide by 2050. As well as the debilitating symptoms associated with the disease, diabetes is linked to a number of serious co-morbidities including heart disease, kidney disease and obesity, therefore accurate diagnosis and careful management is critical to reduce the risk of long-term complications.
Whilst handheld Blood Glucose Monitors (BGMs) and Continuous Glucose Monitors (CGMs) remain a powerful tool for individuals looking to monitor their glycemic control, there is a growing shift for more a.